Market Overview:
The global butorphanol market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of pain, increasing demand for opioid analgesics and growing awareness about pain management. The spray segment is expected to grow at a higher CAGR than other segments during the forecast period. This can be attributed to its easy availability and user-friendly nature. North America is expected to dominate the global butorphanol market in terms of revenue during the forecast period, followed by Europe and Asia Pacific.
Product Definition:
Butorphanol is a synthetic opioid analgesic that is used to treat moderate to severe pain. It is a narcotic and can be habit-forming.
Spray:
Spray is a fine mist and it's used for local anesthesia during surgeries. It also helps in pain management, especially in chronic conditions like arthritis. The growth factor that propels the market growth of Butorphanol is its ability to provide anesthetic and analgesic effects which are very much needed by patients who undergo surgeries or any kind of painful procedures.
It also provides temporary relief from acute pain caused by injuries, bone fractures, etc.
Injection:
Injection is a drug form used for the treatment of pain. It works by changing the way pain signals are processed in the brain. The drug is administered through injections into muscle or under the skin and it provides relief from chronic as well as acute pain. Injection can provide relief from arthritis, backache, headache, and toothache among other pains caused due to inflammation or injury to muscles or nerves.
Application Insights:
The global butorphanol market is segmented by application into human and veterinary. In 2017, the human segment dominated the market with a share of over 90%. The growing usage of opioids for pain management in humans to treat acute as well as chronic pain is expected to drive demand over the forecast period.
In addition, increasing awareness among practitioners regarding effective treatment of pain coupled with rising incidences of drug-related deaths due to opioid overdose are expected to further propel demand in near future. However, owing to high cost and availability only in few countries such as India and China, this drug has not been used extensively for treating pains suffered by patients from developing countries such as Brazil and South Africa. This factor is anticipated to hinder growth during the forecast period despite strong product penetration in developed economies like U.S., Germany etc.
Regional Analysis:
North America was the second-largest regional market in 2017. The region is expected to maintain its dominance until 2030 due to the presence of a large number of manufacturers coupled with high consumer awareness regarding animal health and well-being. However, Asia Pacific is anticipated to be the fastest growing region during the forecast period owing to increasing pet ownership, rising disposable income levels and demand for cost-effective drugs.
The product has been approved by FDA in U.S., European Union (EU) member states as well as Japan for veterinary use only; hence it has limited application scope in human medicine despite being marketed widely across these regions for this purpose since last few years without any prescription requirement under various brand names such as Anectine, Oxyrase, Buprenex and Butrans among others). These products are also sold online without prescription or approval from regulatory authorities which presents major opportunities for global butorphanol market players over the forecast period.
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace and this is expected to drive the demand for Butorphanol in the coming years.
- Rising prevalence of chronic pain: The prevalence of chronic pain is on the rise due to various factors such as lifestyle changes, obesity, and stress. This is likely to boost the demand for Butorphanol in the near future.
- Growing awareness about pain management therapies: There has been a growing awareness about various pain management therapies in recent years. This is likely to propel the demand for Butorphanol in upcoming years.
- Technological advancements: The development of new delivery technologies for Butorphanol will help expand its use beyond traditional settings and increase its adoption among patients suffering from moderate-to-severe pain conditions.. 5) Availability of generic versions: A number of generic versions are available for Butorphanol which will help make it more affordable and accessible to a larger patient population
Scope Of The Report
Report Attributes
Report Details
Report Title
Butorphanol Market Research Report
By Type
Spray, Injection, Tablet
By Application
Human, Veterinary
By Companies
Hikma Pharmaceuticals, Athanas Enterprise Private Limited, Pfizer, Apothecon Pharmaceuticals, Mylan, Novex Pharma, Bristol Myers Squibb, Sanochemia Pharmazeutika, Selectavet, Richter Pharma Ag, Troy Laboratories Nz, Animedica, Boehringer Ingelheim Santé Animale, Ausrichter, Zoetis, Dechra Pharmaceuticals, Faunapharma, Merck KGaA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Butorphanol Market Report Segments:
The global Butorphanol market is segmented on the basis of:
Types
Spray, Injection, Tablet
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Human, Veterinary
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hikma Pharmaceuticals
- Athanas Enterprise Private Limited
- Pfizer
- Apothecon Pharmaceuticals
- Mylan
- Novex Pharma
- Bristol Myers Squibb
- Sanochemia Pharmazeutika
- Selectavet
- Richter Pharma Ag
- Troy Laboratories Nz
- Animedica
- Boehringer Ingelheim Santé Animale
- Ausrichter
- Zoetis
- Dechra Pharmaceuticals
- Faunapharma
- Merck KGaA
Highlights of The Butorphanol Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Spray
- Injection
- Tablet
- By Application:
- Human
- Veterinary
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Butorphanol Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Butorphanol is a medication used to relieve pain. It is also known as buprenorphine and nalbuphine.
Some of the key players operating in the butorphanol market are Hikma Pharmaceuticals, Athanas Enterprise Private Limited, Pfizer, Apothecon Pharmaceuticals, Mylan, Novex Pharma, Bristol Myers Squibb, Sanochemia Pharmazeutika, Selectavet, Richter Pharma Ag, Troy Laboratories Nz, Animedica, Boehringer Ingelheim Sant© Animale, Ausrichter, Zoetis, Dechra Pharmaceuticals, Faunapharma, Merck KGaA.
The butorphanol market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Butorphanol Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Butorphanol Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Butorphanol Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Butorphanol Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Butorphanol Market Size & Forecast, 2018-2028
4.5.1 Butorphanol Market Size and Y-o-Y Growth
4.5.2 Butorphanol Market Absolute $ Opportunity
Chapter 5 Global Butorphanol Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Butorphanol Market Size Forecast by Type
5.2.1 Spray
5.2.2 Injection
5.2.3 Tablet
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Butorphanol Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Butorphanol Market Size Forecast by Applications
6.2.1 Human
6.2.2 Veterinary
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Butorphanol Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Butorphanol Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Butorphanol Analysis and Forecast
9.1 Introduction
9.2 North America Butorphanol Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Butorphanol Market Size Forecast by Type
9.6.1 Spray
9.6.2 Injection
9.6.3 Tablet
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Butorphanol Market Size Forecast by Applications
9.10.1 Human
9.10.2 Veterinary
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Butorphanol Analysis and Forecast
10.1 Introduction
10.2 Europe Butorphanol Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Butorphanol Market Size Forecast by Type
10.6.1 Spray
10.6.2 Injection
10.6.3 Tablet
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Butorphanol Market Size Forecast by Applications
10.10.1 Human
10.10.2 Veterinary
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Butorphanol Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Butorphanol Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Butorphanol Market Size Forecast by Type
11.6.1 Spray
11.6.2 Injection
11.6.3 Tablet
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Butorphanol Market Size Forecast by Applications
11.10.1 Human
11.10.2 Veterinary
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Butorphanol Analysis and Forecast
12.1 Introduction
12.2 Latin America Butorphanol Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Butorphanol Market Size Forecast by Type
12.6.1 Spray
12.6.2 Injection
12.6.3 Tablet
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Butorphanol Market Size Forecast by Applications
12.10.1 Human
12.10.2 Veterinary
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Butorphanol Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Butorphanol Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Butorphanol Market Size Forecast by Type
13.6.1 Spray
13.6.2 Injection
13.6.3 Tablet
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Butorphanol Market Size Forecast by Applications
13.10.1 Human
13.10.2 Veterinary
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Butorphanol Market: Competitive Dashboard
14.2 Global Butorphanol Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Hikma Pharmaceuticals
14.3.2 Athanas Enterprise Private Limited
14.3.3 Pfizer
14.3.4 Apothecon Pharmaceuticals
14.3.5 Mylan
14.3.6 Novex Pharma
14.3.7 Bristol Myers Squibb
14.3.8 Sanochemia Pharmazeutika
14.3.9 Selectavet
14.3.10 Richter Pharma Ag
14.3.11 Troy Laboratories Nz
14.3.12 Animedica
14.3.13 Boehringer Ingelheim Santé Animale
14.3.14 Ausrichter
14.3.15 Zoetis
14.3.16 Dechra Pharmaceuticals
14.3.17 Faunapharma
14.3.18 Merck KGaA
